Abstract: Methods for the controlled activation of the reuterin-production machinery of Lactobacillus reuteri by adding glycerol and other substances during the manufacture of cell-cultures and keeping the produced reuterin in the bacterial cell during preservation and storage. In particular this invention relates to the manufacture of large amounts of L. reuteri that are loaded with reuterin, and the use of such loaded bacteria for applications such as prevention and treatment of diseases, for food applications and the like.

Abstract: The present invention provides probiotic compositions suitable for reducing the incidence and duration of nasal eosinophilia and other parameters associated with birch pollen allergy. In some embodiments, the present invention provides methods and/or compositions suitable for reducing nasal and/or respiratory allergy symptoms. Suitably, such compositions may comprise L. acidophilus, B. lactis or both.

Abstract: This disclosure relates to enhancing growth and/or activity of lactobacilli using a prebiotic formulation which includes iso-malto oligosaccharides and ?-galactosidase; and to enhancing growth and/or activity of bifidobacteria using a prebiotic formulation which includes iso-malto oligosaccharides and ?-glucanase. Other combinations of fibers and enzymes are described below which also stimulate growth and activity of lactobacilli or bifidobacteria. These combinations of enzymes and prebiotics can be taken separately or added to foods, including desserts.

Abstract: The present invention relates to synbiotic compositions comprising probiotic bacterial strains and prebiotic substances that, when combined exhibit synergistic behavior. The synergetic compositions will stimulate the indigenous microflora to restore and reconstitute in vivo gut like conditions after antibiotic associated diarrhea (AAD), and/or other gut infections caused by gastrointestinal pathogens, and relapses thereof, as well as the prevention of said disorders.

Abstract: The invention relates to the area of health-beneficial preparations and production methods thereof, in particular to the use of thermally pre-treated Lactobacillus preparations having specific bonding capacity for Streptococcus mutans for caries prophylaxis. The invention further relates to the Lactobacillus preparations and thermal pasteurization.

Abstract: The present invention relates to the field of infant cereals. In particular, the present invention relates to the field of infant cereals that can be used to strengthen the immune system of the infant and/or that can be used to treat or prevent inflammatory disorders. For example these benefits can be provided by probiotic micro-organisms. An embodiment of the present invention relates to an infant cereal comprising non-replicating probiotic-micro-organisms, for example bioactive heat treated probiotic micro-organisms.

Abstract: The Lactobacillus plantarum CCFM8661 is tolerant to acid and lead ions in vitro which can tolerate lead ions solution with the initial concentration of 150 mg/L, and has a strong capability of binding lead ions, which can reduce the lead level in mice blood, liver, kidney and stomach, significantly improve antioxidant indicators and alleviate pathological symptoms of lead exposed mice.

Abstract: An anti-oxidative Lactobacillus rhamnosus CCFM1107 can relieve chronic alcoholic liver injury, and L. rhamnosus CCFM1107 can be used in preparing dairy products as starter culture. The dairy products of this invention include milk, milk powder, milk capsules or fermented milk containing L. rhamnosus CCFM1107. It has strong abilities of anti-oxidation, scavenging diphenyl picrylhydrazyl (DPPH) radical and hydroxyl radical, inhibiting lipid peroxidation, tolerating cholate, chlorine sodium and pH, and can improve liver function and antioxidative index, lower serum endotoxin level and regulate intestinal flora distribution, thus effectively relieving alcoholic liver injury of mice.

Abstract: Disclosed are: a lactic acid bacterium belonging to Lactobacillus kunkeei, the bacterium having a higher IgA production inducing activity than that of Lactobacillus strain GG (ATCC53103), and a lower mitogenic activity and a lower IL-2 production inducing activity than those of Listeria strain EGD; and a food composition, a pharmaceutical composition, a cosmetic composition, an immunostimulant for preventing the infection by pathogens or viruses that invade through the respiratory or esophageal mucosa, and an intestinal immunostimulant for preventing or alleviating food poisoning, each of which contains the lactic acid bacterium or treated cells of the lactic acid bacterium.

Abstract: The invention relates to Lactobacillus reuteri DSM 17938 for promoting the establishment of healthy and normal cognitive function in young mammals. In particular, the invention relates to the use of Lactobacillus reuteri DSM 17938 for promoting development of the brain structures responsible for cognitive functions (e.g. cortex and hippocampus) and its associated neural pathways and/or to reverse retardation and/or to prevent retardation of the establishment of cognitive functions. Humans or animals and, in particular, a foetus, pre-term or term born infant, toddler or child or a young adult may benefit from the invention.

Abstract: Disclosed are a rice-fermented food composition which contains a rice saccharified liquid fermented with kimchi lactic acid bacteria as an active ingredient and has antibacterial and antiviral effects. More particularly, the present invention relates to a rice lactic acid bacteria fermented food composition which is prepared by adding kimchi lactic acid bacteria to a rice saccharified liquid as a main ingredient and fermenting the mixture, and has antibacterial and antiviral effects against atopic dermatitis and avian influenza virus, and a functional health food comprising the same.

Abstract: The present invention provides probiotic compositions suitable for reducing the incidence and duration of human illness. In particular, the present invention provides methods and compositions suitable for preventing disease in young children. In some particularly preferred embodiments, the present invention finds use in the prevention respiratory disease in children.

Abstract: The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effector. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease.

Abstract: A strain of exopolysaccharide-secreting Lactobacillus brevis, BDLB0001, and an application thereof. The Lactobacillus brevis is deposited at the China General Microbiological Culture Collection Center of the China Committee of Culture Collection for Microorganisms, with a deposit number of CGMCC No. 5223. The Lactobacillus brevis secrets an elevated amount of exopolysaccharide, where the exopolysaccharide secreted is capable of eliciting B lymphocyte proliferation to enhance immunity, and has application prospects in medicaments, healthcare products and food products for immunity enhancement.

Abstract: The present invention relates to a method for producing cheese with good flavour, especially low-salt cheese by using a lactic acid bacteria (LAB) starter culture which is glutamate decarboxylation (GAD) negative. The method may additionally involve inoculating the milk substrate with a GAD-negative Lb. helveticus strain having a high lytic and peptidolytic activity, which further releases glutamate into the milk Additional application of camel chymosin reduces bitterness.

Abstract: According to the invention there is provided a strain of lactic acid bacteria of the genus Lactobacilli obtainable by isolation from resected and washed canine gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Lactobacilli of the present invention are also provided.

Abstract: The invention provides a novel strain of cadmium-removing Lactobacillus plantarum bacterium, CCFM8610, which has a good tolerance to acidic environments. Lactobacillus plantarum CCFM8610 has a good tolerance to cadmium-containing medium and can effectively bind cadmium in vitro. Animal studies have shown that it can effectively reduce tissue cadmium accumulation and facilitate fecal cadmium excretion. Lactobacillus plantarum CCFM8610 has a great potential to be used as an active ingredient in cadmium-removing pharmaceutical drugs and fermented foods.

Abstract: The invention relates to reuterin-producing strains of Lactobacillus brevis. These strains are useful in particular for the treatment or the prevention of conditions resulting from Helicobacter pylori infection.

Abstract: This disclosure relates to enhancing growth and/or activity of lactobacilli using a prebiotic formulation which includes iso-malto oligosaccharides and ?-galactosidase; and to enhancing growth and/or activity of bifidobacteria using a prebiotic formulation which includes iso-malto oligosaccharides and ?-glucanase. Other combinations of fibers and enzymes are described below which also stimulate growth and activity of lactobacilli or bifidobacteria. These combinations of enzymes and prebiotics can be taken separately or added to foods, including desserts.

Abstract: A microorganism strain Lactobacillus plantarum Inducia DSM 21379 for use as hypocholesterolemic, antimicrobial and anti-oxidative agent and as enhancer of the natural defense potential of a subject. L. plantarum Inducia is used for reducing the level of LDL-cholesterol in blood for preventing the cholesterol metabolism disorders and cardiovascular disorders. L. plantarum Inducia enhances simultaneously the natural defense potential and cellular immunity, and as anti-oxidative agent enhances anti-oxidative activity of blood by reducing the level of oxidized low density lipoprotein (ox-LDL). The strain is also used as an antimicrobial agent for lowering risk of Clostridium difficile associated diarrhoeae (CDAD) by preventing germination of C. difficile spores and by suppressing proliferation of its vegetative cells. The compositions comprising L. plantarum Inducia decrease the levels of LDL-cholesterol and ox-LDL in blood, enhance the natural defense potential and lower risk of CDAD.

Abstract: The present invention provides a process for the preparation of freeze dried microorganism composition, comprising the step of (i) subjecting a frozen composition comprising micro-organisms to a drying pressure of from 133 Pa [1000 mT] to 338 Pa [2540 mT] such that at the drying pressure the frozen composition is dried by sublimation of water present in the frozen composition to provide a freeze dried composition comprising the micro-organisms.

Abstract: The invention relates to a new strain of Lactobacillus mucosae which is able to decrease intestinal barrier permeability. This strain is useful in particular for alleviating intestinal barrier dysfunctions.

Abstract: Methods and compositions are hereby disclosed for enhancing weight gain and feed efficiency in a bird, such as a chicken, a turkey, or a laying hen, among others. The methods include administering to the bird a lactic acid producing bacterium (LAB) or combination of LABs. The disclosed methods and compositions also help reduce pathogen infection in the bird and reduce incidence of pathogen contamination in eggs produced by laying hens.

Abstract: This invention provides the use of a microorganism capable of improving both lipid metabolism and sugar metabolism. Specifically, the invention relates to: a lipid metabolism and/or sugar metabolism improver comprising, as an active ingredient, a bacterial cell selected from bacteria belonging to the genus Lactobacillus and the genus Bifidobacterium, a treated product of the bacterial cell, or a mixture thereof, having dual-agonistic activities to peroxisome proliferator activated receptor (PPAR)? and peroxisome proliferator activated receptor (PPAR)?; to a food or a beverage comprising the improver; and to a pharmaceutical composition comprising the improver.

Abstract: Provided is a strain of exopolysaccharide-secreting Lactobacillus plantarum and an application thereof. The deposit number of the strain is CGMCC No. 5222. The strain differs from other strains of Lactobacillus plantarum in the amount of exopolysaccharide secreted, has unique physiological and biochemical characteristics and genetic background, and is a newly isolated and identified strain of Lactobacillus plantarum.

Abstract: The present invention generally relates to the field of sialic acids, in particular to the field of sialic acid enriched food products and their uses. One embodiment of the present invention relates to a food product enriched with food-grade sialic acid producing bacteria and/or a fraction thereof containing sialic acid.

Abstract: The present invention provides a method for enhancing PPAR? expression, comprising administering a subject in need thereof an effective amount of Lactobacillus gasseri PM-A0005, which was deposited under Budapest Treaty in the China Center for Type Culture Collection (CCTCC), China with Deposition No. M 207039.

Abstract: The invention relates to an anhydrous mixture of biologically active probiotic bacteria for topical administration and methods of making thereof. The mixture of the invention is used for hydrating the skin, reducing and preventing fine lines and wrinkles, treating acne and decreasing skin inflammation.

Abstract: The invention is based on a correlation observed between serotonin level and intestinal flora. The invention relates to a relative proportion of bifidobacteria in the intestine and in particular to a product increasing the ratio of bifidobacteria to Clostridia, to be used for raising the serotonin level. The invention also relates to a method for estimating a health risk associated with serotonin depletion by determining a relative proportion between bifidobacteria or Clostridia in the intestine or their ratio to one another. The invention further relates to a method for selecting a form of therapy for raising the serotonin level by determining a relative proportion between bifidobacteria or Clostridia in the intestine or their ratio to one another.

Abstract: The present invention relates to the use of the probiotic strain of Lactobacillus paracasei subsp. paracasei deposited at the CNCM under the reference I-3689, for inhibiting in vivo infection by Listeria monocytogenes.

Abstract: The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effector. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease.

Abstract: The invention is based on a correlation observed between visceral fat and gut flora. The invention relates to a product increasing the relative proportion of bifidobacteria in the intestines and to be used for preventing formation of visceral fat or for reducing the amount thereof in the body. In particular, the product increases the ratio of bifidobacteria to Clostridia. The invention also relates to determining visceral fat in the body by determining the relative proportion of bifidobacteria or Clostridia or their ratio to each other in the intestines. The invention further relates to a method for estimating, in the same manner, the health risk associated with obesity.

Abstract: The invention includes methods and compositions for treating an animal to inhibit the incidence and growth of E. coli O157:H7 and other pathogenic bacteria. The treatment method comprises administering a therapeutically effective amount of Lactobacillus animalis or one or a combination of a number of other probiotic bacteria to an animal. An alternative treatment method comprises administering a therapeutically effective amount of a lactic acid producing bacterium such as Lactobacillus animalis in combination with a lactate utilizing bacterium such as Propionibacterium freudenreichii.

Abstract: An antimicrobial peptide having potent antibacterial activity against Listeria monocytogenes and Staphylococcus aureus is described. Also described is an isolated Lactobacillus salivarius DPC6502 strain as deposited with the National Collection of Industrial and Marine Bacteria under the Accession No. NCIMB 41840, and variants thereof, wherein the isolated bacteria and variants thereof express an antimicrobial peptide of the invention.

Abstract: An anti-fatty liver agent containing a cell and/or a culture of the lactic acid bacterium Latobacillus gasseri as an active ingredient is provided. Also disclosed is a pharmaceutical agent having an anti-fatty liver activity or an anti-fatty liver beverage or food containing a cell and/or a culture of the lactic acid bacterium Latobacillus gasseri as an active ingredient. Methods of treating fatty liver in a subject by administering a cell and/or a culture of the lactic acid bacterium Latobacillus gasseri are also provided.

Abstract: Provided herein are microbial inoculants for use in increasing plant growth, plant productivity and/or soil quality, comprising strains of one or more bacterial species selected from Lactobacillus parafarraginis, Lactobacillus buchneri, Lactobacillus rapi and Lactobacillus zeae. Optionally the microbial inoculants also comprise a strain of Acetobacter fabarum and/or a strain of Candida ethanolica. Also provided are fertilizer compositions comprising said microbial inoculants.

Abstract: The present invention relates to gram positive bacteria with increased stress resistance and/or improved storage characteristics. In particular, the invention relates to gram positive bacterium which accumulate intracellular trehalose. The gram positive bacterium according to the invention lack cellobiose-specific PTS system IIC component (PtcC) activity. The gram positive bacterium may further lack trehalose 6-phosphate phosphorylase (TrePP) activity. The gram positive bacterium may further overexpress trehalose transporters. The invention further relates to compositions comprising such gram positive bacterium as well as methods and uses thereof.

Abstract: Ferulate esterase producing bacterial strains or functional mutants thereof and methods of using ferulate esterase producing bacterial strains as forage additives are disclosed.

Abstract: The present invention provides a method for reducing the viscosity of a microorganism-containing suspension or concentrate and a method for obtaining a microorganism concentrate, wherein a monosaccharide and/or disaccharide and/or sugar alcohol is added to said microorganism-containing suspension or concentrate.

Abstract: The present invention generally relates to the field of sialic acids, in particular to the field of sialic acid enriched food products and their uses. One embodiment of the present invention relates to a food product enriched with food-grade sialic acid producing bacteria and/or a fraction thereof containing sialic acid.

Abstract: The present invention relates to a process for providing purified bacteria-containing concentrates, comprising at least the steps of adding an aqueous solution to a first bacteria-containing concentrate to provide a bacteria-containing suspension, wherein the volume of the added aqueous solution is in the range of 0.3 liters to 10 liters per liter of said first bacteria-containing concentrate; and concentrating said bacteria-containing suspension to provide a second bacteria-containing concentrate. Further, the present invention relates to the purified concentrates per se.

Abstract: The present invention relates to a new strain of Lactobacillus delbrueckii subsp. bulgaricus, suitable for use in the treatment or prevention of Helicobacter pylori infection.

Abstract: The present invention provides novel strains of probiotics for use in the gastrointestinal tract of a pet. The probiotics of the present invention are capable of fermenting starch to produce lactic acid and/or hydrogen peroxide anti-pathogenic metabolites. The present invention also provides a novel method for identifying the effectiveness of a pet probiotic in vitro. The method simulates the introduction of a probiotic candidate in the gastrointestinal tract of a pet and measures the anti-pathogenic effectiveness of the probiotic.

Abstract: The present invention generally relates to the field of probiotic bacteria. In particular, the present invention relates to natural derivatives of the Lactobacillus johnsonii strain CNCM I-1225 with improved properties. For example, the present invention relates to a natural derivative of the Lactobacillus johnsonii strain CNCM I-1225 that is deficient in D-lactic acid production and exhibits an improved viability during product storage.

Abstract: The invention relates to a microorganism, of the order of lactic acid bacteria or analog, fragment, derivative, mutant or combination thereof. Said microorganism, or analog, fragment, derivative, mutants or combinations thereof can be co-aggregated with at least Staphylococcus aureus or Pseudomonas aeruginosa.

Abstract: The present invention relates to a novel wild-type Lactococcus lactis subsp. cremoris bacteria strain with increased vitamin K2 production and mutants and variants thereof and methods for preparation of a fermented food or feed product enriched in vitamin K2 and a vitamin K enriched edible product for amelioration and/or prevention of vitamin K deficiency. The present invention also relates to the fermented food or feed product and the edible product obtainable by the methods herein and to the wild-type Lactococcus lactis subsp. cremoris bacteria strain for use in treatment and/or prevention of vitamin K deficiency in a mammal, such as a human.

Abstract: The object of the invention is a new strain of Lactobacillus buchneri A deposited in the Collection of Industrial Microorganisms in the Institute of Agricultural and Food Biotechnology in Warsaw, under the number KKP 2047 p. The invention also concerns composition and a multi-component preparation for starch-rich plant preservation comprising this new strain, uses thereof and the method of silage production or starch-rich plant preservation.

Abstract: Provided is a novel lactic acid bacterium strain which is capable of suppressing production of volatile sulfur compounds by oral bacteria, has no cariogenicity and no causative role in infective endocarditis, and is safe in an oral cavity, and provided is an agent for preventing, improving and/or treating oral diseases and discomforts by use of the bacterial strain.

Abstract: The present invention provides an oral vaccine against a bacterial infectious disease (e.g., typhoid fever, cholera, or dysentery). The oral vaccine of the present invention is a capsule formulation in which a transformed microorganism that expresses a flagellin antigen protein or that secretes a flagellin antigen protein out of the cell of the microorganism is encapsulated with an acid-resistant membrane. Examples of the microorganism include intestinal bacteria belonging to the genus Bifidobacterium, the genus Lactobacillus, the genus Lactococcus, and the like. The form of the capsule formulation may be any one of a seamless capsule formulation, a soft capsule formulation, and a hard capsule formulation.

Abstract: An encapsulation system is provided comprising nitrogen-purge, instant bonding encapsulation method. Specifically, the encapsulation system comprises a composition, a two-piece capsule comprising a capsule cap and a capsule body; a gas to purge oxygen from the composition within the capsule; and a sealing solution to seal the capsule cap to the capsule body. Associated methods for encapsulating compositions using the encapsulation system are also provided.